0.17
9.09%
-0.017
After Hours:
.17
Virios Therapeutics Inc stock is traded at $0.17, with a volume of 872.96K.
It is down -9.09% in the last 24 hours and down -12.37% over the past month.
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$0.187
Open:
$0.18
24h Volume:
872.96K
Relative Volume:
0.91
Market Cap:
$4.72M
Revenue:
-
Net Income/Loss:
$-5.30M
P/E Ratio:
-0.3091
EPS:
-0.55
Net Cash Flow:
$-4.87M
1W Performance:
-12.46%
1M Performance:
-12.37%
6M Performance:
-64.52%
1Y Performance:
-81.62%
Virios Therapeutics Inc Stock (VIRI) Company Profile
Name
Virios Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Virios Therapeutics Inc Stock (VIRI) Latest News
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Virios Therapeutics Inc Inc. (VIRI) Price Performance: Understanding Market Sentiment - The InvestChronicle
It would be worthwhile to take a closer look at Virios Therapeutics Inc (VIRI) - US Post News
Vicor Corporation Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVICR - AccessWire
MONDAY INVESTOR DEADLINE: Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitVICR - AccessWire
Virios Therapeutics Inc (VIRI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Virios Therapeutics Inc (VIRI)’s Market Momentum: Closing Strong at 0.19, Up 7.78 - The Dwinnex
Take off with Virios Therapeutics Inc (VIRI): Get ready for trading - SETE News
Stock Performance Spotlight: Virios Therapeutics Inc (VIRI) Ends the Day at 0.21, Down by -3.94 - The Dwinnex
Virios Therapeutics Inc (VIRI) did well last session? - US Post News
Reviewing Virios Therapeutics (NASDAQ:VIRI) & Xencor (NASDAQ:XNCR) - Defense World
Virios Therapeutics Inc (VIRI) expanding its growth trajectory ahead - SETE News
VIRI’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Analyzing VIRI’s price-to-book ratio for the last quarter - US Post News
VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024… - MSN
VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024… - Yahoo Finance
HC Wainwright Cuts Virios Therapeutics (NASDAQ:VIRI) Price Target to $0.20 - Defense World
Virios Therapeutics Announces Second Quarter 2024 Financial Results - Marketscreener.com
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Virios Therapeutics Announces Second Quarter 2024 Financial Results - GlobeNewswire
Virios Therapeutics Announces Second Quarter 2024 Financial Results - StockTitan
Virios Therapeutics (VIRI) to Release Earnings on Thursday - Defense World
Virios Therapeutics Inc (VIRI)’s Market Momentum: Closing Strong at 0.19, Down -8.25 - The Dwinnex
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - ForexTV.com
VIRIVirios Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - WDRB
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - GlobeNewswire
Taking on analysts’ expectations and winning: Virios Therapeutics Inc (VIRI) - SETE News
Virios Therapeutics Inc (VIRI) deserves closer scrutiny - US Post News
Ratios Reveal: Breaking Down Virios Therapeutics Inc (VIRI)’s Financial Health - The Dwinnex
Virios Therapeutics Inc (VIRI) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Virios Therapeutics Announces Completion of Enrollment in - GlobeNewswire
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - StockTitan
Prepare Yourself for Liftoff: Virios Therapeutics Inc (VIRI) - SETE News
Does Virios Therapeutics Inc (NASDAQ: VIRI) Still Need To Convince Analysts? - Stocks Register
Upward Trajectory: Virios Therapeutics Inc (VIRI) Posts a Slidee, Closing at 0.25 - The Dwinnex
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket - Benzinga
How does Virios Therapeutics Inc (VIRI) change from a tortoise to a hare? - SETE News
In the Green: Virios Therapeutics Inc (VIRI) Closes at 0.24, Up/Down -2.36 from Previous Day - The Dwinnex
Virios Therapeutics Inc (VIRI) is a good investment, but the stock may be overvalued - US Post News
Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Large Decline in Short Interest - Defense World
Gaining Ground: Virios Therapeutics Inc (VIRI) Closes Lower at 0.26, Down -1.53 - The Dwinnex
The Virios Therapeutics Inc (VIRI) had a good session last reading, didn’t it? - US Post News
VIRI’s Stock Market Expedition: Traversing Gains and Losses in 2023 - The InvestChronicle
Zika Virus Therapeutics Market size is set to grow by USD 4.17 billion from 2024-2028, Availability of serology kit for qualitative diagnosis of zika virus infection to boost the market growth, Technavio - Yahoo Finance
Virios Therapeutics Inc (VIRI) Stock: A Comprehensive 52-Week Review - The InvestChronicle
How does Virios Therapeutics Inc (VIRI) change from a tortoise to a hare? – Sete News - SETE News
Virios Therapeutics Inc (VIRI) is an excellent investment, but the stock is overvalued/undervalued right now – US Post ... - US Post News
Viridien: Information on the total number of voting rights and shares - GlobeNewswire Inc.
Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Up 70.1% in June - Defense World
Virios Therapeutics Inc Stock (VIRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):